卡博替尼联合阿替利珠单抗治疗转移性前列腺癌(CONTACT-02):一项3期开放标签随机试验的最终分析
CONTACT-02研究纳入575例既往接受过一种雄激素受体通路抑制剂(ARPI)后进展、伴盆腔外软组织转移的转移性去势抵抗性前列腺癌(mCRPC)患者,随机分配至卡博替尼联合阿替利珠单抗组或ARPI转换组。最终分析显示,联合组显著改善无进展生存期(中位6.3个月 vs 4.2个月,HR 0.65,p=0.0007),但总生存期无显著差异(中位14.8个月 vs 15.0个月,HR 0.89,p=0.30)。
要点
- 卡博替尼联合阿替利珠单抗较ARPI转换显著改善mCRPC患者的无进展生存期(HR 0.65,p=0.0007)。
- 联合组与ARPI转换组的总生存期无显著差异(HR 0.89,p=0.30)。
- 联合组3-4级不良事件发生率为56%,ARPI转换组为26%。
核心结论
- 卡博替尼联合阿替利珠单抗这一不直接靶向雄激素受体信号通路的新型药物组合,可能成为既往ARPI治疗后进展、伴软组织转移的mCRPC患者的有用治疗选择。
研究设计与样本
- CONTACT-02是一项开放标签、随机、3期研究,在24个国家(欧洲、北美、亚太和拉丁美洲)的184个中心入组患者。
- 入组标准为年龄18岁及以上、ECOG体能状态评分为0或1、mCRPC伴可测量盆腔外软组织转移(淋巴结或内脏)、既往接受过一种ARPI后进展的男性患者。
- 患者按1:1随机分配至卡博替尼(40 mg口服每日一次)联合阿替利珠单抗(1200 mg静脉注射每3周一次)组或ARPI转换(阿比特龙1000 mg口服每日一次联合泼尼松5 mg口服每日两次,或恩扎卢胺160 mg口服每日一次)组,随机化使用基于网络的交互式响应技术系统,按肝转移存在与否、既往多西他赛治疗和首次ARPI治疗时疾病状态分层。
- 双主要终点为前400例随机分配患者的无进展生存期(无进展生存期意向治疗人群)和所有随机分配患者的总生存期(意向治疗人群)。
- 安全性在所有至少接受一剂研究治疗的患者中评估。
主要发现
- 2020年8月20日至2023年6月7日期间,575例患者随机分配至卡博替尼联合阿替利珠单抗组(n=289)或ARPI转换组(n=286)。
- 中位随访11.8个月(IQR 9.9-19.3)后,卡博替尼联合阿替利珠单抗组较ARPI转换组显著改善无进展生存期(中位6.3个月[95% CI 6.2-8.8] vs 4.2个月[3.7-5.7];HR 0.65[95% CI 0.50-0.84],p=0.0007)。
- 中位随访23.1个月(IQR 17.4-30.5)后,卡博替尼联合阿替利珠单抗组与ARPI转换组的总生存期无显著差异(中位14.8个月[95% CI 13.4-16.7] vs 15.0个月[13.0-18.5];HR 0.89[95% CI 0.72-1.10],p=0.30)。
- 卡博替尼联合阿替利珠单抗组284例患者中158例(56%)发生任何原因的3-4级不良事件,ARPI转换组284例患者中74例(26%)发生;联合组最常见为高血压(24例[8%])和贫血(23例[8%]),ARPI转换组最常见为贫血(18例[6%])。
- 研究者认为与治疗相关的严重不良事件在卡博替尼联合阿替利珠单抗组284例患者中发生45例(16%),ARPI转换组284例患者中发生11例(4%);联合组最常见为腹泻(5例[2%]),ARPI转换组最常见为丙氨酸氨基转移酶升高(2例[1%])。
关键数值与推荐
- 卡博替尼联合阿替利珠单抗组中位无进展生存期6.3个月(95% CI 6.2-8.8),ARPI转换组4.2个月(95% CI 3.7-5.7),HR 0.65(95% CI 0.50-0.84),p=0.0007。
- 卡博替尼联合阿替利珠单抗组中位总生存期14.8个月(95% CI 13.4-16.7),ARPI转换组15.0个月(95% CI 13.0-18.5),HR 0.89(95% CI 0.72-1.10),p=0.30。
- 卡博替尼联合阿替利珠单抗组任何原因3-4级不良事件发生158例(56%),ARPI转换组74例(26%)。
- 卡博替尼联合阿替利珠单抗组治疗相关严重不良事件发生45例(16%),ARPI转换组11例(4%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic soft-tissue metastases that has progressed on an androgen receptor pathway inhibitor (ARPI) have a poor prognosis with few treatment options. We aimed to assess efficacy and safety of cabozantinib, a tyrosine kinase inhibitor with immunomodulatory properties, plus the PD-L1 inhibitor atezolizumab in these patients. METHODS: CONTACT-02 is an open-label, randomised, phase 3 study that enrolled patients at 184 sites across 24 countries (in Europe, North America, Asia-Pacific, and Latin America). Men aged 18 years and older, with an Eastern Cooperative Oncology Group performance status score of 0 or 1, and who had mCRPC and measurable extrapelvic soft-tissue metastases (lymph node or visceral) that had progressed on one previous ARPI were eligible. Patients were randomly assigned 1:1 to cabozantinib (40 mg orally once daily) plus atezolizumab (1200 mg intravenously once every 3 weeks) or ARPI switch (abiraterone 1000 mg orally once-daily plus prednisone 5 mg orally twice-daily, or enzalutamide 160 mg orally once-daily) using a web-based interactive response technology system and stratified by the presence of liver metastasis, previous docetaxel therapy, and disease status at first ARPI initiation. Dual primary endpoints were progression-free survival in the first 400 randomly assigned patients (progression-free survival intention-to treat [ITT] population) and overall survival in all randomly assigned patients (ITT population). Safety was assessed in all patients who received at least one dose of study treatment. Although the study is ongoing, with some patients remaining in follow-up, this analysis represents the protocol-specified final analysis. This trial is registered with ClinicalTrials.gov, NCT04446117. FINDINGS: Between Aug 20, 2020 and June 7, 2023, 575 patients were randomly assigned to cabozantinib plus atezolizumab (n=289) or ARPI switch (n=286). Most patients were White (440 [77%]) or Asian (78 [14%]). After a median follow-up of 11·8 months (IQR 9·9-19·3), cabozantinib plus atezolizumab significantly improved progression-free survival versus ARPI switch (median 6·3 months [95% CI 6·2-8·8] vs 4·2 months [3·7-5·7]; hazard ratio [HR] 0·65 [95% CI 0·50-0·84], p=0·0007). After a median follow-up of 23·1 months (IQR 17·4-30·5), overall survival was not significantly different between the cabozantinib plus atezolizumab and ARPI switch groups (median 14·8 months [95% CI 13·4-16·7] vs 15·0 months [13·0-18·5]; HR 0·89 [95% CI 0·72-1·10], p=0·30). Any-cause grade 3-4 adverse events occurred in 158 (56%) of 284 patients given cabozantinib plus atezolizumab and 74 (26%) of 284 patients given ARPI switch; the most common in the cabozantinib plus atezolizumab group were hypertension (24 [8%] of 284 patients) and anaemia (23 [8%]) and the most common in the ARPI switch group was anaemia (18 [6%] of 284 patients). Serious adverse events deemed related to treatment occurred in 45 (16%) of 284 patients in the cabozantinib plus atezolizumab group and in 11 (4%) of 284 patients in the ARPI switch group; the most common with cabozantinib plus atezolizumab was diarrhoea (five [2%] of 284 patients) and the most common with ARPI switch was increase in alanine aminotransferase (two [1%] of 284 patients). Adverse events of any cause led to discontinuation of all components of study treatment in 49 (17%) of 284 patients in the cabozantinib plus atezolizumab group and in 42 (15%) of 284 patients in the ARPI switch group. No treatment-related deaths occurred. INTERPRETATION: Cabozantinib plus atezolizumab, a novel drug combination that does not directly target androgen receptor signalling, could be a useful treatment option for patients with mCRPC and soft-tissue metastases who have progressed on an ARPI. FUNDING: Exelixis in partnership with Ipsen, Takeda, and Roche.
引用
- Agarwal N, Azad AA, Carles J, et al. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Lancet Oncol. 2025. PMID: 40523369. doi:10.1016/S1470-2045(25)00209-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。